Innovator’s Pitch Challenge

Vote for Us

Interested in Connecting? Please contact:
Michael Kokesh
President & CEO

Message the company or request a 1:1 meeting here

ViCardia was founded in 2017 and is based in San Francisco. Our management team, board of directors, and our scientific advisors are some of the brightest stars in the heart failure constellation. The management team has prior experience taking companies from start up to successful exit at significant multiples to the original investment by leading venture capital firms, in the process taking one company public. ViCardia is developing a breakthrough heart failure therapy, GP 531, a potent, long-lasting, mitotropic agent, administered as an infusion therapy, that targets mitochondrial dysfunction, reversing the decline in the production of cellular energy, and improving cardiac function